THANKS CRAMER!! $MRNA
Moderna Shares Extend Gains as Jim Cramer Talks About Potential Cancer Vaccine
TheStreet's founder, Jim Cramer, says Moderna is working on the development of a messenger-RNA based vaccine against certain forms of cancer.
Moderna Inc. (MRNA) shares jumped higher Friday after Jim Cramer said the drugmaker is nearing the development of a vaccine that could protect against certain forms of cancer.
Cramer, speaking on CNBC's Squawk on the Street program, said the developments were "pre-clinical" but nonetheless remarkable and are based on the drugmaker's messenger-RNA delivery techniques, which it used to develop its mRNA-1273 coronavirus vaccine.
"This is not an RNA messenger vaccine company for COVID," Cramer said. "This is a new way to be able to stop diseases and people I know that are working with this company know that they may have a vaccine against certain forms of cancer."
"That's how powerful RNA messenger is," he added "I've been reluctant to say that but I have it from more than one source. I have it from two sources, both of whom are involved ... and it's just incredible. We're taking about a Noble Prize. It works."
Moderna shares were marked 5.2% higher in early trading Friday and changing hands at $156.00 each.
Alongside a similar messenger-RNA vaccine developed by Pfizer (PFE) and its German partner BioNTech (BNTX) , Moderna has taken the lead role in the government's accelerating rollout.
Late Thursday, Moderna said its mRNA-1273 coronavirus vaccine, which earned Emergency Use Authorization from the U.S. Food & Drug Administration in late December, should generate around $18.4 billion in sales this year and deliver the drugmaker's first annual profit since 2011.
CEO Stephane Bancel said Moderna plans to produce as many as 1 billion doses of mRNA-1273 this year, adding that it's working on boosters that would address the growing spread of coronavirus variants first identified in the United Kingdom and South Africa.
Moderna Inc. (MRNA) shares jumped higher Friday after Jim Cramer said the drugmaker is nearing the development of a vaccine that could protect against certain forms of cancer.
C?ramer, speaking on CNBC's Squawk on the Street program, said the developments were "pre-clinical" but nonetheless remarkable and are based on the drugmaker's messenger-RNA delivery techniques, which it used to develop its mRNA-1273 coronavirus vaccine.
"This is not an RNA messenger vaccine company for COVID," Cramer said. "This is a new way to be able to stop diseases and people I know that are working with this company know that they may have a vaccine against certain forms of cancer."
"That's how powerful RNA messenger is," he added "I've been reluctant to say that but I have it from more than one source. I have it from two sources, both of whom are involved ... and it's just incredible. We're taking about a Noble Prize. It works."
Moderna shares were marked 5.2% higher in early trading Friday and changing hands at $156.00 each.
Alongside a similar messenger-RNA vaccine developed by Pfizer (PFE) and its German partner BioNTech (BNTX) , Moderna has taken the lead role in the government's accelerating rollout.
Late Thursday, Moderna said its mRNA-1273 coronavirus vaccine, which earned Emergency Use Authorization from the U.S. Food & Drug Administration in late December, should generate around $18.4 billion in sales this year and deliver the drugmaker's first annual profit since 2011.
CEO Stephane Bancel said Moderna plans to produce as many as 1 billion doses of mRNA-1273 this year, adding that it's working on boosters that would address the growing spread of coronavirus variants first identified in the United Kingdom and South Africa.
